Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

Bristol Myers Squibb has climbed 17% year-to-date yet continues to trade at a discount to pharmaceutical peers despite delivering $12.9 billion in Q2 revenue and 153% EPS growth. The company's newer growth portfolio now represents nearly 60% of total revenue and posted 15% year-over-year expansion, effectively countering legacy drug patent cliff concerns that have weighed on the stock.

The discount valuation comes despite several catalysts gaining attention on the Street. BMY maintains a 3.95% dividend yield and has a $5 billion buyback program underway. Market chatter around potential acquisition interest from AstraZeneca (AZN) has added speculative momentum, though no formal offer has been announced.

Analysts are increasingly bullish on BMY's pipeline execution, arguing the market has underpriced the shift in revenue mix toward higher-growth assets. The company's ability to replace declining legacy sales with double-digit growth from newer franchises is beginning to register in sell-side models, driving a louder bull case across Wall Street research desks.